Medincell (XPAR:MEDCL) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:MEDCL Medincell SA XPAR:MEDCL
77 GF Score
Price €26.88
GF Value €21.90
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Medincell Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Medincell's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

XPAR:MEDCL vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Medincell's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medincell Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medincell's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Medincell's Margin of Safety % (DCF Earnings Based) falls into.


XPAR:MEDCL
77GF Score
Medincell SA XPAR:MEDCL
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Medincell (XPAR:MEDCL) Overvalued in 2026?

Based on GuruFocus' analysis, Medincell stock appears to be overvalued. The current stock price of €26.88 is trading 22.7% above its estimated GF Value™ of €21.90. GuruFocus considers Medincell to be Modestly Overvalued.

Key valuation signals for XPAR:MEDCL:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €21.90 vs. price of €26.88 (22.7% above fair value)
  • GF Score™: 77/100 with 5 warning signs

No single metric tells the full story. See the XPAR:MEDCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medincell Business Description

Other Exchanges 0ACH:UKMEDCLp:UKMEB:Germany
Address 3 rue des Freres Lumiere, Jacou, FRA, 34830
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.
77GF Score

Get the complete analysis for XPAR:MEDCL

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€26.88
Price
€21.90
GF Value